Everence Capital Management’s Meridian Bioscience Inc VIVO Stock Holding History

Everence Capital Management’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-8,520	Closed	-$283	–	801
2022 Q4	$283	Hold	8,520	–	–	0.02%	574
2022 Q3	$269K	Hold	8,520	–	–	0.02%	548
2022 Q2	$259K	Hold	8,520	–	–	0.02%	563
2022 Q1	$221K	Buy	+8,520	New	+$203K	0.02%	660
2021 Q2	–	Sell	-8,520	Closed	-$224K	–	754
2021 Q1	$224K	Sell	8,520 -4,440	-34%	-$106K	0.02%	653
2020 Q4	$242K	Hold	12,960	–	–	0.02%	590
2020 Q3	$220K	Buy	+12,960	New	+$252K	0.02%	560

Other funds holding VIVO

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Everence Capital Management's VIVO Position: Q1 2023 in Review

Everence Capital Management sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 8,520 shares — an estimated $283 sold.

Everence Capital Management first reported a position in VIVO in Q3 2020 and held it in 7 quarters. The position peaked at $269K in Q3 2022. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

Everence Capital Management reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
Everence Capital Management sold 8,520 Meridian Bioscience Inc shares in Q1 2023, an estimated $283.
Everence Capital Management first reported a position in Meridian Bioscience Inc in Q3 2020 and held it in 7 quarters.
Everence Capital Management's Meridian Bioscience Inc position peaked at $269K in Q3 2022.
2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on Everence Capital Management's 13F filing for Q1 2023, filed 4 Apr 2023.